ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Search by Abstract Number Results

  • Abstract Number: 0866 • ACR Convergence 2024

    Cross-sectional Analysis of Erosive Hand Osteoarthritis and Fracture Risk

    Avanika Mahajan1, carolyn mead harvey2, Chris Grilli3 and Megan Sullivan3, 1Mayo Clinic - - Scottsdale, AZ, Phoenix, AZ, 2Mayo Clinic Florida, Jacksonville, FL, 3Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Erosive hand osteoarthritis (EHOA) is a subtype of hand OA that primarily impacts the interphalangeal joints resulting in subchondral bone erosion and cortical destruction.…
  • Abstract Number: 0866 • ACR Convergence 2023

    A Novel 3D-Synovium-Immune Microenvironment Mimics Macrophage-Synovial Fibroblast Interactions in Inflammatory Arthropathies

    André Tiaden1, Simone Häner Massimi1, Ulrich Walker2, Diego Kyburz3 and Stavros Giaglis1, 1Laboratory for Experimental Rheumatology, Department of Biomedicine, University of Basel, Basel, Switzerland, 2Basel University Hospital, Basel, Switzerland, 3University Hospital Basel, Basel, Switzerland

    Background/Purpose: Autoimmunity, trauma, or infection lead to devastating arthropathies, within enormous socioeconomic impact due to its high frequency and chronicity. The development of novel treatments…
  • Abstract Number: 0866 • ACR Convergence 2022

    Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab

    Sheila Angeles-Han1, Grant Schulert1, Megan Quinlan-Waters1, Alexandra Duell1, Jennifer Huggins1, Tiffany Nguyen2, Cameron Sapp2, Sumit Sharma3, Sunil Srivastava4 and Arjun Sood2, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Eye Institute, Cincinnati, OH, 3Cole Eye Institute, Cleveland Clinic, Cleveland, OH, 4Cole Eye Institute, Cleveland Clinic, Cincinnati, OH

    Background/Purpose: Pediatric uveitis is commonly associated with rheumatic disease and can lead to sight-threatening complications. Initial treatment are glucocorticoids and subsequently methotrexate (MTX) and TNF…
  • Abstract Number: 0866 • ACR Convergence 2021

    Characteristics Associated with Poor COVID-19 Outcomes in People with Systemic Lupus Erythematosus (SLE): Data from the COVID-19 Global Rheumatology Alliance (GRA)

    Manuel Ugarte-Gil1, Graciela Alarcn2, Andrea Seet3, Zara Izadi3, Ali Duarte-Garcia4, Cristina Reategui-Sokolova5, Ann Clarke6, Leanna Wise7, Guillermo Pons-Estel8, Maria José Santos9, Sasha Bernatsky10, Sandra Lúcia Ribeiro11, Samar Al Emadi12, Jeffrey Sparks13, Tiffany Hsu14, Kristin D'Silva15, Naomi Patel15, Emily Gilbert16, Maria Valenzuela-Almada17, Andreas Jnsen18, Gianpiero Landolfi19, Micaela Fredi20, Tiphaine Goulenok21, Mathilde Devaux22, Xavier Mariette23, Viviane Queyrel24, Vasco C Romão25, Graça Sequeira26, Rebecca Hasseli27, Bimba Franziska Hoyer28, Reinhard Voll29, Christof Specker30, Roberto Baez31, Vanessa Castro Coello32, Edgard Neto33, Gilda Ferreira34, Odirlei Andre Monticielo35, Emily Sirotich36, Jean Liew37, Jonathan Hausmann38, Paul Sufka39, Rebecca Grainger40, Suleman Bhana41, Wendy Costello42, Zachary Wallace43, Lindsay Jacobsohn44, Anja Strangfeld45, Elsa Frazão Mateus46, Kimme Hyrich47, Laure Gossec48, Loreto Carmona1, Saskia Lawson-Tovey47, Lianne Kearsley-Fleet49, Martin Schaefer50, Pedro Machado51, Philip Robinson52, Milena Gianfrancesco3 and Jinoos Yazdany3, 1Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, 2University of Alabama at Birmingham, Birmingham, AL, 3University of California San Francisco, San Francisco, CA, 4Mayo Clinic, Rochester, MN, 5Hospital Guillermo Almenara Irigoyen, Lima, Peru, 6University of Calgary, Calgary, AB, Canada, 7LAC+USC/Keck Medicine of USC, Pasadena, CA, 8Centro Regional de Enfermedades Autoinmunes y Reumaticas (CREAR), Rosario, Argentina, 9Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, 10McGill University, Montréal, QC, Canada, 11Universidade Federal do Amazonas, Amazonas, Brazil, 12Hamad medical corporation, Doha, Qatar, 13Brigham and Women's Hospital, Boston, MA, 14Brigham and Women's Hospital, Jamaica Plain, MA, 15Massachusetts General Hospital, Boston, MA, 16Mayo Clinic, Jacksonville, FL, 17Division of Rheumatology, Mayo Clinic, Rochester, MN, 18Lund University, Lund, Sweden, 19Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy, 20Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 21Internal Medicine Department, Bichat Claude Bernard Hospital, Paris, France, 22Service de Médecine Interne, CHI Poissy Saint Germain, Poissy, France, 23Université Paris- Saclay, Rheumatology, Paris, France, 24University Hospital of Nice, Nice, France, 25Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, 26Centro Hospitalar Universitário do Algarve, Unidade de Faro, Faro, Portugal, 27Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, 28Universittsklinikum Schleswig-Holstein, Kiel, Germany, 29Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, 30Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, 31Hospital Francisco Lopez Lima, General Roca, Rio Negro, Argentina, 32Sanatorio Güemes, Buenos Aires, Argentina, 33UNIFESP, São Paulo, Brazil, 34Federal University of Minas Gerais, Belo Horizonte, Brazil, 35Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 36McMaster University, Hamilton, ON, Canada, 37Boston University, Boston, MA, 38Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 39HealthPartners, Eagan, MN, 40University of Otago, Wellington, New Zealand, 41Crystal Run Health, Montvale, NJ, 42Irish Children's Arthritis Network, Bansha, Ireland, 43Massachusetts General Hospital, Newton, MA, 44University of California San Francisco, Antioch, CA, 45Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 46Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, 47University of Manchester, Manchester, United Kingdom, 48Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, 49Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 50German Rheumatism Research Center, Berlin, Germany, 51Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 52Faculty of Medicine, The University of Queensland, Herston, Australia

    Background/Purpose: Preliminary data in people with SLE suggested that disease activity as well as SLE treatment at time of COVID-19 acquisition impact COVID-19 outcomes over…
  • Abstract Number: 0866 • ACR Convergence 2020

    Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies

    Joan Merrill1, Matthew Studham2, Eric Morand3, Aida Aydemir2, Cristina Vazquez Mateo2, Alex Rolfe2, Amy Kao2 and Robert Townsend2, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 3Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: Atacicept, a dual inhibitor of the B lymphocyte stimulator and a proliferation-inducing ligand (APRIL), has been associated with a reduction of flares in the…
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology